Keyphrases
T Cell Response
79%
High-risk Human Papillomavirus (HR-HPV)
67%
CD8+ T Cells
56%
T Cells
56%
Vaccine Strategy
50%
Adenovirus Vaccine
48%
Adenoviral
45%
Vaccination
42%
Immunization
42%
Vector Encoding
42%
Adenovirus Vector
37%
Immune Response
35%
Oncogenic Human Papillomavirus
34%
HIV-1 Envelope
33%
Cervix
33%
Tumor Antigen
33%
Papillomavirus Infections
33%
Chronic Viral Infection
33%
Therapeutic Vaccine
33%
Cancer Vaccine
33%
Vaccine Target
33%
Immunodominant Epitopes
33%
Viremia
33%
Tumor Progression
33%
Epitope
33%
Murine gammaherpesvirus 68 (MHV-68)
33%
Primates
33%
Serotype 19A
33%
Viral-vectored Vaccine
33%
Dominant Antigen
33%
Vaccinees
33%
Mucosal Vaccine
33%
Viral Replication
33%
Virus
27%
Macaca Fascicularis
27%
Latent Infection
25%
Invariant Chain
25%
CD8+ T Cell Response
24%
Dominant Epitopes
22%
Viral Challenge
22%
Prophylactic Vaccine
18%
Intramuscularly
16%
E1 Protein
16%
Human Papillomavirus Vaccine
16%
E2 Protein
16%
Immunology and Microbiology
T Cell
100%
Adenovirus Vector
95%
Papillomaviridae
82%
Adenoviridae
71%
Cytotoxic T-Cell
68%
Epitope
53%
Virus
51%
Macaca fascicularis
50%
Wart Virus
40%
Serotype
39%
Viral Disease
39%
Human Immunodeficiency Virus 1
33%
Tumor Vaccine
33%
Virus-Like Particle
33%
Gammaherpesvirus
33%
Immunogenicity
33%
Tumor Antigen
33%
Human Adenovirus C
33%
Immune Response
31%
Human Adenovirus 5
24%
Binding Antibody
20%
Antibody Response
20%
Neutralizing Antibody
20%
Invariant Chain
18%
Herpesviridae
16%
